Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
75 results about "Cancer development" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The development of cancer takes place in a multi-step process. As the cells become more abnormal, they gain new capabilities, such as the ability to release growth factors and digestive enzymes. The cells continue to divide, impacting nearby normal cells, often reducing the function of the affected organ.
Targeted innate immunity
InactiveUS20060135459A1Hybrid immunoglobulinsSugar derivativesAbnormal tissue growthCancer targeting
Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a CpG oligodeoxynucleotide. Also provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer, comprising administering an effective amount of the cancer therapeutic agent. The methods may also include reducing immunoregulatory T cell activity in the individual.
Owner:UNIV OF SOUTHERN CALIFORNIA
Methods and uses thereof of prosaposin
InactiveUS20100144603A1Extended half-lifeFacilitating recombinant protein expressionAntibacterial agentsBiocideAbnormal tissue growthLymphatic Spread
The invention relates to methods for treating of tumor metastasis, methods for preventing, inhibiting, and predicting tumor recurrence and tumor metastasis, and methods of preventing cancer development for one at risk of developing cancer, for one diagnosed with a benign cancer, and / or for one diagnosed with malignant cancer. The invention also relates to methods of treating angiogenesis-dependent diseases and disorders. In addition, the invention provides: (1) a method for screening for tumor / cancer derived angiogenesis and metastasis factors; (2) a method for screening for compounds that inhibit angiogenesis and metastasis; (3) a method for screening for compounds that promote anti-angiogenesis and anti-metastasis activities; (4) a method for cancer prognosis evaluation; (5) a method for predicting the tissue specificity of a metastatic cancer; (6) a method for determining likelihood of metastasis; and (7) a method for cancer prognosis evaluation by the surveillance of metastasis development.
Owner:CHILDRENS MEDICAL CENT CORP
Immunomodulating Agent, Anti-Cancer Agent and Health Food Containing Monoacetyldiacylglycerol Derivatives
The uses of mono acetyl diacyl glycerol derivatives extracted from deer antler for immunomodulating agent disclosed. Medical supplies and health foods containing the same as an effective ingredient also disclosed. Mono acetyl diacyl glycerol derivatives shows significantly effect for immuno modulation including immune enhancing. In the case of inducing cancer in a hamster by injecting cancer cell line, cancer development was delayed by activating lymphocytes, monocytes, and dendritic cells that are important factors to promote immunity and apoptosis of cancer cell was induced by promoting cytotoxicity of immune cell against cancer cell. Also in the case of mouse induced septic shock, it shows 100% survival rate even after lapse of 120 hours by control of immune function and suppression effect apoptosis. Therefore, mono acetyl diacyl glycerol derivatives according to the present invention can be effectively used for an immunomodulating agent, a sepsis treatment, a cancer treatment, and a health food for an immune modulation or the prevention of cancer.
Owner:ENZYCHEM LIFESCI CORP
Monoacetyldiacylglycerol derivative for the treatment of sepsis
The uses of mono acetyl diacyl glycerol derivatives extracted from deer antler for immunomodulating agent disclosed. Medical supplies and health foods containing the same as an effective ingredient also disclosed. Mono acetyl diacyl glycerol derivatives shows significantly effect for immuno modulation including immune enhancing. In the case of inducing cancer in a hamster by injecting cancer cell line, cancer development was delayed by activating lymphocytes, monocytes, and dendritic cells that are important factors to promote immunity and apoptosis of cancer cell was induced by promoting cytotoxicity of immune cell against cancer cell. Also in the case of mouse induced septic shock, it shows 100% survival rate even after lapse of 120 hours by control of immune function and suppression effect apoptosis. Therefore, mono acetyl diacyl glycerol derivatives according to the present invention can be effectively used for an immunomodulating agent, a sepsis treatment, a cancer treatment, and a health food for an immune modulation or the prevention of cancer.
Owner:ENZYCHEM LIFESCI CORP
Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample
ActiveUS7252976B2Sugar derivativesMicrobiological testing/measurementProgenitorAngiogenesis growth factor
The present invention involves the use of quantitative RT-PCR to identify AC133 as a marker. AC133 is prevalent on endothelial progenitor cells (EPCs), which are important cells in angiogenesis. Therefore, the invention is applied to ascertain the quantity of EPCs in a subject, and to diagnose and monitor angiogenesis, for example, in injured tissues and in cancer development and progression.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Use of anti-α5β1 antibodies to inhibit cancer cell proliferation
InactiveUS7662384B2Prevent proliferationPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntiangiogenesis TherapyAntiendomysial antibodies
The present invention provides methods for direct killing of cancer cells using anti-α5β1 antibodies. Generally, the method comprises contacting a cancer cell that expresses α5β1 on its surface with an anti-α5β1 antibody, and thereby inducing the death of the cancer cell. The methods of the invention may be employed at an early stage of cancer development in a patient to prevent tumor establishment. In addition, the methods may be used to treat previously formed tumors especially in cancer that have not proven susceptible to anti-angiogenesis therapy. The methods may be employed as a combination therapy of anti-α5β1 antibodies together with cancer chemotherapeutic agents or other molecular-based cancer therapeutic agents.
Owner:ABBOTT BIOTHERAPEUTICS CORP
Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
InactiveUS20050260210A1Prevent proliferationPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAbnormal tissue growthAntiangiogenesis Therapy
The present invention provides methods for direct killing of cancer cells using anti-α5β1 antibodies. Generally, the method comprises contacting a cancer cell that expresses α5β1 on its surface with an anti-α5β1 antibody, and thereby inducing the death of the cancer cell. The methods of the invention may be employed at an early stage of cancer development in a patient to prevent tumor establishment. In addition, the methods may be used to treat previously formed tumors especially in cancer that have not proven susceptible to anti-angiogenesis therapy. The methods may be employed as a combination therapy of anti-α5β1 antibodies together with cancer chemotherapeutic agents or other molecular-based cancer therapeutic agents.
Owner:ABBOTT BIOTHERAPEUTICS CORP
Therapeutic use of tumor necrosis factor-alpha mutein
Improved methods for treating neoplastic diseases such as cancer are provided by using muteins of human tumor necrosis factor-alpha (TNF-alpha). Compared to wild-type human TNF-alpha these therapeutic TNF muteins have higher specific anti-tumor activity, but with much reduced systemic toxicity and milder side effects such chills and fever. In addition, potentially synergistic, novel combinations of the inventive TNF-alpha muteins with other anti-neoplastic agents are provided for effectively treating patients having particular types of cancer or malignancy or at particular stages of cancer development.
Method for inhibiting cancer development by fatty acid synthase inhibitors
A method for inhibiting or preventing cancer development by the administration of fatty acid synthase (FAS) inhibitors. In particular, the present invention prohibits or delays the development of invasive cancer from pre-malignant (non-invasive) lesions that express FAS. Compositions containing FAS inhibitors also are provided, as well as methods for administering the FAS inhibitors and compositions to patients in need thereof.
Owner:FASGEN +1
Phylogenetic Analysis of Mass Spectrometry or Gene Array Data for the Diagnosis of Physiological Conditions
ActiveUS20070259363A1Facilitates interplatform comparabilityMedical simulationMedical data miningDiseasePotential biomarkers
A universal data-mining platform capable of analyzing mass spectrometry (MS) serum proteomic profiles and / or gene array data to produce biologically meaningful classification; i.e., group together biologically related specimens into clades. This platform utilizes the principles of phylogenetics, such as parsimony, to reveal susceptibility to cancer development (or other physiological or pathophysiological conditions), diagnosis and typing of cancer, identifying stages of cancer, as well as post-treatment evaluation. To place specimens into their corresponding clade(s), the invention utilizes two algorithms: a new data-mining parsing algorithm, and a publicly available phylogenetic algorithm (MIX). By outgroup comparison (i.e., using a normal set as the standard reference), the parsing algorithm identifies under and / or overexpressed gene values or in the case of sera, (i) novel or (ii) vanished MS peaks, and peaks signifying (iii) up or (iv) down regulated proteins, and scores the variations as either derived (do not exit in the outgroup set) or ancestral (exist in the outgroup set); the derived is given a score of “1”, and the ancestral a score of “0”—these are called the polarized values. Furthermore, the shared derived characters that it identifies are potential biomarkers for cancers and other conditions and their subclasses.
Owner:AMRI HAKIMA +2
Detection and diagnosis of smoking related cancers
InactiveUS20060078885A1Sugar derivativesMicrobiological testing/measurementCancer genesLow risk group
Gene probes for specific regions of chromosome 3 (3p21.3) and chromosome 10 (10q22) have been found to be tools for the diagnosis and prognosis of smoking related cancers such as non-small cell lung cancer (NSCLC). For example, these probes can be used with fluorescence in situ hybridization (FISH), and used to stratify smokers into high and low risk groups, as well as determine a patients susceptibility to the development of smoking related cancers.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Animal models of cancer development and metastasis
InactiveUS20060101531A1Reduce transferIncreased metastasisVectorsEnzymesHuman animalLymphatic Spread
Transgenic, non-human animal model of cancer, methods of making such animals and methods of using such animals to screen test compounds are provided.
Owner:FRED HUTCHINSON CANCER RES CENT +1
Kit and method for diagnosis of lung cancer in chronic obstructive pulmonary disease (COPD) patients through meta-genome analysis
InactiveCN108239670AMicrobiological testing/measurementObstructive Pulmonary DiseasesTherapeutic effect
Owner:MD HEALTHCARE INC
Phosphopeptides as melanoma vaccines
ActiveUS20120177669A1Reduce riskTumor rejection antigen precursorsPeptide/protein ingredientsAntigenLymphatic Spread
We characterized a total of 175 HLA-DR-associated phosphopeptides using sequential affinity isolation, biochemical enrichment, mass spectrometric sequencing and comparative analysis. Many were derived from source proteins which may have roles in cancer development, growth and metastasis. Most were expressed exclusively by either melanomas or transformed B cells, suggesting the potential to define cell type-specific phosphatome “fingerprints”. We generated HLA-DRβ1*0101-restricted CD4+ T cells specific for a phospho-MART-1 peptide identified in two melanoma cell lines. These T cells showed specificity for phosphopeptide-pulsed antigen presenting cells as well as for intact melanoma cells. MHC II-restricted phosphopeptides recognizable by human CD4+ T cells are potential targets for cancer immunotherapy.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Tissue chip for detecting backbone metastatic carcinoma prognosis related molecule sign
InactiveCN101013086AImprove clinical treatment effectRational treatment strategyMicrobiological testing/measurementColor/spectral properties measurementsCancer developmentLarge sample
The invention relates to the biotechnology area, and the spinal metastatic cancer prognosis judgment is the key to correct determine clinical development strategy, and in the invention, for the present spinal metastatic cancer related molecular biology prognosis judgment evaluation lacking problem, it constructs the spinal metastatic cancer prognosis related molecular marker tissue chip. By screening the clinical data and determining the random data spinal metastatic cancer pathological wax block to produce the spinal metastatic cancer tissue chip; selecting a variety of molecular markers and tissue chips for immunohistochemistry or in-situ hybridization, and through image analysis and quantitative measurement to analyze the expression instance of each molecular marker in the spinal metastatic cancer pathological specimens, and to analyze the relationship between the molecular markers expression and the patients prognosis, and screening the molecular markers which are closely related to the spinal metastatic cancer prognosis. The tissue chip provides a high-throughput, large sample, rapid detection tool for screening the spinal metastatic cancer prognostic related molecular markers, and provides a theoretical basis for the rational determination of the spinal metastatic cancer development strategies.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Translocation and mutant ros kinase in human non-small cell lung carcinoma
ActiveCN101528921AOrganic active ingredientsAntibody mimetics/scaffoldsProto-Oncogene Tyrosine-Protein Kinase ROSNucleotide
In accordance with the invention, a novel gene translocation, (4p15, 6q22), in human non-small cell lung carcinoma (NSCLC) that results in a fusion proteins combining part of Sodium-dependent Phosphate Transporter lsoform NaPi-3b protein (SLC34A2) with Proto- oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase has now been identified. The SLC34A2-ROS fusion protein is anticipated to drive the proliferation and survival of a subgroup of NSCLC tumors. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of the new fusion protein enables new methods for determining the presence of these mutant ROS kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.
Owner:CELL SIGNALING TECHNOLOGY
Spontaneously immortalized prostate cancer cell line
InactiveUS20140017721A1Fast bondingPrevent proliferationSugar derivativesMicrobiological testing/measurementProstate cancer cellAnticarcinogen
This disclosure provides prostate cancer cell lines established from spontaneously immortalized, extremely tumorigenic and clonogenic primary prostate tumor. These cell lines represent unique cancer cell and cancer stem cell (CSC) models for preclinical prostate cancer studies and CSC-targeted drug development, which is of high value for pharmaceutic companies producing anti-cancer agents, as well as for the broad range of basic and translational research focused on cancer cell and CSC biology, stem cell behavior, cancer development and metastasis.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK
DC-CIK cell and anti-PD-1 antibody composition and application thereof
ActiveCN106890330APromote activationLimited efficacyPharmaceutical delivery mechanismMammal material medical ingredientsCancer cellImmunocompetence
The invention belongs to the fields of immunology, tumor microenvironment and tumor immnuotherapy and provides a DC-CIK cell and anti-PD-1 antibody composition which is used for preparing immune drugs for treating cancers or delaying cancer development. The invention provides a combined immune composition for treating cancers, and the composition is formed by an effective dose of DC-CIK cells and an anti-PD-1 antibody. According to the combined immune composition, the immunocompetence for killing the cancer cells in a patient body can be effectively enhanced, and a cancer clinic treatment effect can be improved or the cancer development can be delayed hopefully.
Owner:珠海横琴壹加医疗健康管理有限公司
Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors
InactiveUS20140378531A1Prevents pancreatic cancer progressionNovel roleOrganic active ingredientsCompound screeningCancer preventionPattern recognition receptor
The disclosure herein relates to the novel finding that pattern recognition receptor activation is central to pancreatic cancer progression, and provides antagonists of pattern recognition receptors (PRRs), including the TLRs 4, 7, and 9, and the CLR dectin-1, for treatment and prevention of pancreatic cancer and pancreatic inflammation. The inventors have discovered that cancer development and progression can be prevented by pattern recognition receptor inhibition, a powerful finding with important clinical and therapeutic implications.
Owner:NEW YORK UNIV
Cancer-related MicroRNA identification method based on miRNA-gene regulation module
The invention relates to data mining in bioinformatics, and particularly to a method for identifying the cancer-related miRNA through a miRNA-gene regulation module. The method comprises the steps ofperforming difference comparison of gene expression data; processing the gene expression data and miRNA expression data; constructing the miRNA-gene interaction matrix; calculating a miRNA-gene correlation coefficient, obtaining a miRNA-gene correlation matrix, performing fuzzy clustering on the miRNA; constructing a combined miRNA-gene interaction matrix and a miRNA-gene correlation matrix, calculating absolute average correlation degree of the gene with each miRNA, adding the gene into the miRNA according to absolute average correlation degree for constructing the miRNA-gene regulating module; calculating the correlation degree of the miRNA in each module, and ordering according to the correlation degree. The main process is presented in a graph 1. The method can be used for acquiring the cancer-related miRNA for searching the function and the mechanism in a cancer development and generating process, screening the miRNA biological mark in cancer early-period diagnosis, and acquiringtargets in targeted treatment of the cancer.
Owner:HUNAN UNIV
Embryonic stem cell markers for cancer diagnosis and prognosis
InactiveUS20100009858A1Reduce in quantityImprove forecast accuracySugar derivativesNucleotide librariesTumour tissueCancers diagnosis
A method of predicting the development of a cancer in a patient, comprises procuring a sample of tumour tissue from the patient, determining the expression pattern of embryonic stem cell genes in the tissue, comparing the expression pattern with the corresponding expression pattern of embryonic stem cell genes in tumour tissue of reference patients with known disease histories. Also disclosed are microarrays and DNA / RNA probes for use in the method.
Owner:CHUNDSELL MEDICALS AB
Compositions and libraries comprising recombinant t-cell receptors and methods of using recombinant t-cell receptors
Owner:HEALTH RES INC
Graded Expression of Snail as Marker of Cancer Development and DNA Damage-Based Diseases
InactiveUS20100061973A1Increase capacityPromote cell migrationOrganic active ingredientsPeptide/protein ingredientsNucleic acid sequencingCancer development
The invention relates to the graded expression level of SNAIL gene or its expression products, as a marker of the capacity of epithelial and mesenchymal tumours and / or cancers for disseminating to other tissues or organs. The invention further relates to a transgenic non-human mammal comprising in its genome a transgene that comprises a nucleic acid sequence encoding the SNAIL protein, and the use of SNAIL as a marker of epithelial and mesenchymal tumours and / or cancers as well as in DNA damage-based diseases In addition, the invention relates to the use of SNAIL as a therapeutic and diagnostic target for said pathologies.
Owner:SANCHEZ GARCIA ISIDRO +2
Identification of neoplasms by detection of genetic insertions and deletions
InactiveUS7090978B2Predictive valueSugar derivativesMicrobiological testing/measurementNeoplasmNucleotide sequencing
The detection of insertions and / or deletions in reiterated nucleotide sequences in tissues provides an identification of neoplastic changes that are associated with malignancy. The mutations are preferably detected by PCR based amplification of target sequences using selected primers, followed by standard analytic procedures. The detection of these mutations is useful as a diagnostic tool for cancer development and has direct application for cancer prognosis.
Owner:AGILENT TECH INC
Beta-hcg promoter based tumor restrictive gene expression for cancer theraphy
The present invention relates to promoters, enhancers and other regulatory elements that direct expression within tumor cells, comprising nucleotide sequences from the 5' regulatory region, and transcriptionally active fragments thereof, that control expression of a testicular carcinoma related protein, beta-HCG. Specifically provided are expression vectors, host cells and transgenic animals wherein an beta-HCG regulatory region is capable of controlling expression of a heterologous gene, over-expressing an endogenous gene or an inhibitor of a pathological process or knocking out expression of a specific gene believed to be important in cancer development and / or progression. The invention also relates to methods for using said vectors, cells and animals for screening candidate molecules for agonists and antagonists of cancer development and / or progression. The invention further relates to compositions and methods for modulating expression of compounds within tumor cells, and to screening compounds that modulate expression within tumor cells. Methods for using the molecules and compounds identified by the screening assays for therapeutic treatments also are provided.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND
Human EZH2 mutant gene and application thereof
The invention provides human EZH2 mutant gene, a mutant gene detecting method and application in therapeutic effect evaluation of chemotherapy of a gastric cancer. The gastric cancer is the main cancer which always affects Chinese people and is easy to cause death, the therapeutic effect evaluation of chemotherapy of the gastric cancer mainly depends on an iconography means and serological indicators, but the iconography means and the serological indicators are poor in timeliness and low in specificity. Mutation of the EZH2 mutant gene occurs on a 1234 position to a 1240 position of a number 19 intron, and a preferable mutant gene sequence is as shown in SEQ ID NO: 1-4, and has not been reported; and basis and foundation can be provided for analysis of a gastric cancer development and progression mechanism, drug development and the like. In addition, the application of the EZH2 mutant gene and a detecting method thereof facilitate the therapeutic effect evaluation of chemotherapy of the gastric cancer and illness monitoring so as to guide formulation of a therapeutic schedule.
Owner:FUJIAN MEDICAL UNIV +1
Method for examination of carcinogenic risk
ActiveUS20150376716A1Reduce cancer riskImprove the situationCompound screeningApoptosis detectionBacteroidesIntestinal microorganisms
The present invention provides a method capable of detecting a cancer and / or a carcinogenic risk, and a reagent for the detection thereof. The present invention also provides a method for screening for a pharmaceutical drug for reducing a carcinogenic risk and a pharmaceutical composition. Since cancer development closely correlates with alteration in gut microbiota, cancer development and / or a risk of cancer development are detected by detecting alteration in gut microbiota and a secondary bile acid produced by an intestinal bacterium. The present invention further provides a method for screening for a pharmaceutical drug with a gut microbiota as an index, and a pharmaceutical composition.
Owner:JAPANESE FOUND FOR CANCER RES
Formula of anti-oxidation anti-cancer fruit and vegetable juice and preparation technology for fruit and vegetable juice
ActiveCN102697118AImprove responsePrevent cancerFood preparationOrganic sulfide compoundBeta-Carotene
The invention relates to the technical field of fruit and vegetable beverage, in particular to a formula of anti-oxidation anti-cancer fruit and vegetable juice and a preparation technology for the fruit and vegetable juice. The formula comprises vegetables, fruits, nut seeds, spices and the like proportioned according to a principle in certain ratio; the prepared fruit and vegetable juice contains antioxidant, free radical resistant phytochemical elements (lycopene, beta-carotene, organic sulfides and the like) and anti-inflammatory substances (flavonoids, curcumin, omega 3-unsaturated fatty acid and the like), so that the cancer development process can be effectively disturbed, the response ability of the anti-oxidation and anti-inflammatory immune system of human body is enhanced, cancer can be effectively prevented, and the fruit and vegetable juice has certain health-care curative effects on cancer patients; and due to the formula of purely natural materials, the fruit and vegetable juice is pure in mouthfeel, does not have irritation, and is suitable for wide crowds.
Owner:北京呵维企业管理中心
LONG NON-CODING RNA LncHIFCAR/MIR31HG AND ITS APPLICATIONS
InactiveUS20190022127A1Facilitates the recruitment of HIF-1αOrganic active ingredientsMicrobiological testing/measurementRegimenCancers diagnosis
The invention is related to LncHIFCAR (long noncoding HIF-1α co-activating RNA) / MIR31HG and its applications in cancer diagnosis, cancer therapy, prognosis predication of a cancer and determination of therapeutic regimen of a cancer. The present invention identifies a hypoxia-inducible lncRNA, LncHIFCAR (long noncoding HIF-1α co-activating RNA) / MIR31HG, and describes its oncogenic role as a HIF-1α co-activator that regulates the HIF-1 transcriptional network, crucial for cancer development.
Owner:TAIPEI MEDICAL UNIV +2
Detection and diagnosis of lung or upper airway cancers using 10Q22 as a biomarker
Gene probes for specific regions of chromosome 3 (3p21.3) and chromosome 10 (10q22) have been found to be tools for the diagnosis and prognosis of smoking related cancers such as non-small cell lung cancer (NSCLC). For example, these probes can be used with fluorescence in situ hybridization (FISH), and used to stratify smokers into high and low risk groups, as well as determine a patients susceptibility to the development of smoking related cancers.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com